These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23246637)

  • 1. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.
    Carbone M; Mells GF; Pells G; Dawwas MF; Newton JL; Heneghan MA; Neuberger JM; Day DB; Ducker SJ; ; Sandford RN; Alexander GJ; Jones DE
    Gastroenterology; 2013 Mar; 144(3):560-569.e7; quiz e13-4. PubMed ID: 23246637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.
    Cortez-Pinto H; Liberal R; Lopes S; Machado MV; Carvalho J; Dias T; Santos A; Agostinho C; Figueiredo P; Loureiro R; Martins A; Alexandrino G; Cotrim I; Leal C; Presa J; Mesquita M; Nunes J; Gouveia C; Vale AHE; Alves AL; Coelho M; Maia L; Pedroto I; Banhudo A; Pinto JS; Gomes MV; Oliveira J; Andreozzi V; Calinas F
    United European Gastroenterol J; 2021 Jul; 9(6):699-706. PubMed ID: 34102008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
    Poupon RE; Eschwège E; Poupon R
    J Hepatol; 1990 Jul; 11(1):16-21. PubMed ID: 1975819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
    Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
    Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
    [No Abstract]   [Full Text] [Related]  

  • 7. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up.
    Jones DE; Al-Rifai A; Frith J; Patanwala I; Newton JL
    J Hepatol; 2010 Nov; 53(5):911-7. PubMed ID: 20800924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
    Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
    Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
    [No Abstract]   [Full Text] [Related]  

  • 9. Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC).
    Kaps L; Grambihler A; Yemane B; Nagel M; Labenz C; Ploch P; Michel M; Galle PR; Wörns MA; Schattenberg JM
    Dig Dis Sci; 2020 Oct; 65(10):3006-3013. PubMed ID: 31853781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
    Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
    Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study.
    Zhu J; Shi Y; Zhou X; Li Z; Huang X; Han Z; Wang J; Wang R; Ding J; Wu K; Han Y; Fan D
    Front Med; 2013 Jun; 7(2):255-63. PubMed ID: 23179137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
    Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
    Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
    Almasio PL; Floreani A; Chiaramonte M; Provenzano G; Battezzati P; Crosignani A; Podda M; Todros L; Rosina F; Saccoccio G; Manenti F; Ballardini G; Bianchi FP; Scheuer PJ; Davies SE; Craxì A
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1645-52. PubMed ID: 11121914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A two-year follow-up study on the efficacy of ursodeoxycholic acid on primary biliary cirrhosis in different stages].
    Zhu JY; Li ZS; Yan W; Wang JH; Zhou XM; Wang RA; Huang XF; Shi YQ; Dong XY; Han ZY; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2010 Oct; 18(10):735-9. PubMed ID: 21059288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
    Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
    J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.
    Chang ML; Chen WT; Chan TM; Lin CY; Chang MY; Chen SC; Chien RN
    Front Immunol; 2022; 13():869018. PubMed ID: 35663951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
    Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
    Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.